Logo image of CURI

CURIOSITYSTREAM INC (CURI) Stock Fundamental Analysis

NASDAQ:CURI - Nasdaq - US23130Q1076 - Common Stock - Currency: USD

2.57  -0.19 (-6.72%)

After market: 2.53 -0.04 (-1.56%)

Fundamental Rating

3

CURI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 71 industry peers in the Entertainment industry. CURI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, CURI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CURI has reported negative net income.
In the past year CURI had a positive cash flow from operations.
In the past 5 years CURI always reported negative net income.
In the past 5 years CURI always reported negative operating cash flow.
CURI Yearly Net Income VS EBIT VS OCF VS FCFCURI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

CURI has a worse Return On Assets (-16.89%) than 78.79% of its industry peers.
Looking at the Return On Equity, with a value of -23.77%, CURI is doing worse than 60.61% of the companies in the same industry.
Industry RankSector Rank
ROA -16.89%
ROE -23.77%
ROIC N/A
ROA(3y)-32.91%
ROA(5y)-33.84%
ROE(3y)-44.62%
ROE(5y)-54.51%
ROIC(3y)N/A
ROIC(5y)N/A
CURI Yearly ROA, ROE, ROICCURI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

CURI's Gross Margin of 48.40% is in line compared to the rest of the industry. CURI outperforms 56.06% of its industry peers.
CURI's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CURI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15%
GM growth 5YN/A
CURI Yearly Profit, Operating, Gross MarginsCURI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 50 -50 -100 -150

More info and screens

5

2. Health

2.1 Basic Checks

CURI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CURI has been increased compared to 1 year ago.
There is no outstanding debt for CURI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CURI Yearly Shares OutstandingCURI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
CURI Yearly Total Debt VS Total AssetsCURI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -0.91, we must say that CURI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.91, CURI is not doing good in the industry: 77.27% of the companies in the same industry are doing better.
There is no outstanding debt for CURI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -0.91
ROIC/WACCN/A
WACC9.06%
CURI Yearly LT Debt VS Equity VS FCFCURI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 1.90 indicates that CURI should not have too much problems paying its short term obligations.
CURI's Current ratio of 1.90 is fine compared to the rest of the industry. CURI outperforms 74.24% of its industry peers.
CURI has a Quick Ratio of 1.90. This is a normal value and indicates that CURI is financially healthy and should not expect problems in meeting its short term obligations.
CURI has a Quick ratio of 1.90. This is in the better half of the industry: CURI outperforms 77.27% of its industry peers.
Industry RankSector Rank
Current Ratio 1.9
Quick Ratio 1.9
CURI Yearly Current Assets VS Current LiabilitesCURI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

CURI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.00%, which is quite impressive.
The Revenue has decreased by -8.56% in the past year.
CURI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.82% yearly.
EPS 1Y (TTM)75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88%
Revenue 1Y (TTM)-8.56%
Revenue growth 3Y12.82%
Revenue growth 5YN/A
Sales Q2Q%-19.36%

3.2 Future

Based on estimates for the next years, CURI will show a very strong growth in Earnings Per Share. The EPS will grow by 25.98% on average per year.
Based on estimates for the next years, CURI will show a small growth in Revenue. The Revenue will grow by 7.98% on average per year.
EPS Next Y76.97%
EPS Next 2Y38.68%
EPS Next 3Y25.53%
EPS Next 5Y25.98%
Revenue Next Year-13.04%
Revenue Next 2Y-2.56%
Revenue Next 3Y2.22%
Revenue Next 5Y7.98%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CURI Yearly Revenue VS EstimatesCURI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
CURI Yearly EPS VS EstimatesCURI Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

CURI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CURI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CURI Price Earnings VS Forward Price EarningsCURI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

CURI's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CURI is cheaper than 72.73% of the companies in the same industry.
CURI's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CURI is cheaper than 60.61% of the companies in the same industry.
Industry RankSector Rank
P/FCF 55.29
EV/EBITDA 14.38
CURI Per share dataCURI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as CURI's earnings are expected to grow with 25.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.68%
EPS Next 3Y25.53%

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 4.36%, CURI is a good candidate for dividend investing.
CURI's Dividend Yield is rather good when compared to the industry average which is at 5.24. CURI pays more dividend than 95.45% of the companies in the same industry.
CURI's Dividend Yield is rather good when compared to the S&P500 average which is at 2.27.
Industry RankSector Rank
Dividend Yield 4.36%

5.2 History

CURI does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
CURI Yearly Dividends per shareCURI Yearly Dividends per shareYearly Dividends per share 2024 2025 0.02 0.04 0.06 0.08

5.3 Sustainability

DPN/A
EPS Next 2Y38.68%
EPS Next 3Y25.53%
CURI Yearly Income VS Free CF VS DividendCURI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2019 2020 2021 2022 2023 -20M -40M -60M

More info and screens

CURIOSITYSTREAM INC

NASDAQ:CURI (2/21/2025, 8:11:21 PM)

After market: 2.53 -0.04 (-1.56%)

2.57

-0.19 (-6.72%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryEntertainment
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-19 2025-03-19/amc
Inst Owners9.39%
Inst Owner Change8.71%
Ins Owners6.48%
Ins Owner Change2.22%
Market Cap142.58M
Analysts82.22
Price Target2.81 (9.34%)
Short Float %1.03%
Short Ratio1.25
Dividend
Industry RankSector Rank
Dividend Yield 4.36%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date03-14 2025-03-14 (0.03)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-23.89%
Min EPS beat(2)-76.49%
Max EPS beat(2)28.7%
EPS beat(4)2
Avg EPS beat(4)-12.94%
Min EPS beat(4)-76.49%
Max EPS beat(4)43.07%
EPS beat(8)2
Avg EPS beat(8)-52.32%
EPS beat(12)6
Avg EPS beat(12)-25.07%
EPS beat(16)9
Avg EPS beat(16)-13.98%
Revenue beat(2)0
Avg Revenue beat(2)-5.93%
Min Revenue beat(2)-9.67%
Max Revenue beat(2)-2.18%
Revenue beat(4)0
Avg Revenue beat(4)-5.55%
Min Revenue beat(4)-9.67%
Max Revenue beat(4)-2.03%
Revenue beat(8)3
Avg Revenue beat(8)-6.75%
Revenue beat(12)5
Avg Revenue beat(12)-4.17%
Revenue beat(16)7
Avg Revenue beat(16)11.31%
PT rev (1m)0%
PT rev (3m)59.42%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.98%
EPS NY rev (1m)0%
EPS NY rev (3m)5.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.75
P/FCF 55.29
P/OCF 55.39
P/B 2.29
P/tB 5.03
EV/EBITDA 14.38
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)0.05
FCFY1.81%
OCF(TTM)0.05
OCFY1.81%
SpS0.93
BVpS1.12
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.89%
ROE -23.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.4%
FCFM 4.98%
ROA(3y)-32.91%
ROA(5y)-33.84%
ROE(3y)-44.62%
ROE(5y)-54.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15%
GM growth 5YN/A
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0.02%
Cap/Sales 0.01%
Interest Coverage N/A
Cash Conversion 38.56%
Profit Quality N/A
Current Ratio 1.9
Quick Ratio 1.9
Altman-Z -0.91
F-Score6
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)0.52%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.22%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88%
EPS Next Y76.97%
EPS Next 2Y38.68%
EPS Next 3Y25.53%
EPS Next 5Y25.98%
Revenue 1Y (TTM)-8.56%
Revenue growth 3Y12.82%
Revenue growth 5YN/A
Sales Q2Q%-19.36%
Revenue Next Year-13.04%
Revenue Next 2Y-2.56%
Revenue Next 3Y2.22%
Revenue Next 5Y7.98%
EBIT growth 1Y62.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year90.84%
EBIT Next 3Y27.14%
EBIT Next 5Y15.73%
FCF growth 1Y104.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y104.14%
OCF growth 3YN/A
OCF growth 5YN/A